BIOCRATES expands management board: New Chief Technology Officer (CTO) Dr. Ralph Zahn

08-Dec-2010 - Austria

BIOCRATES Life Sciences AG has employed Dr. Ralph Zahn as new CTO (Chief Technology Officer), since October 2010. „The constant development of our products and the affiliated technical and scientific assignments made a CTO necessary. Dr. Zahn and his expertise are a valuable enrichment to our organisation“, says Elgar Schnegg, MBA, CEO of BIOCRATES.

He holds a PhD in natural sciences and has a wealth of experience in the field of biotech. After he graduated from biology, he worked as research associate and earned the doctors degree in 1994 at the Max-Planck-Institute for Biochemistry in Munich. At the Cambridge University he absolved a post-graduate doctors degree. He habilitated 2001 at the Institute for Molecular Biology and Biophysics at the Eidgenössische Technische Hochschule in Zurich. During his career, he was managing director at BioSafety GmbH and founder and CEO of allprion AG.

Other news from the department people

Most read news

More news from our other portals

Last viewed contents

Novartis and Gen-Probe Agree to Extend and Expand Blood Screening Collaboration - Companies will work together to protect the world's supply of donated blood from infectious diseases until 2025

Cell Therapeutics' subsidiary PanGenex introduces technology for high-throughput, cell-based screening of new cancer targets - Technology described at international scientific conference

LION Bioscience, Ltd. Signs Collaboration Agreement with European Molecular Biology Laboratory

DiagnoCure partner launches new prostate cancer test in Europe

On the trail of cancer stem cells - What goes on inside and between individual cells during the very earliest stages of tumor development?

On the trail of cancer stem cells - What goes on inside and between individual cells during the very earliest stages of tumor development?

BIOBASE übernimmt Proteome Inc. von Incyte Corp. - Internationale Firmenübernahme im Bereich Bioinformatik

Icon Genetics and Novoplant announce broad license agreement

Researchers identify non-culturable microbes from bloodstream infections

Scientists Discover New Molecular Markers for Testicular Cancer - Researchers in the Netherlands use new technology from Applied Biosystems to identify different expression patterns of microRNA molecules in normal and cancerous cells

Hospira Announces $2 Billion Agreement to Acquire Mayne Pharma

MOLOGEN: Executive Board orients towards new commercial tasks

DeveloGen and Scientists from IPK Gatersleben Publish Data on Key Trigger for Regenerating Insulin Producing Cells - Study Provides Additional Support in Fight to Treat Diabetes